Recent News


Carmell Therapeutics to Present at the 21st Annual BIO CEO & Investor Conference in New York

Carmell Therapeutics, a pioneer in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, today announced that President and CEO, Randy Hubbell, will present at the 21st Annual BIO CEO & Investor Conference on Monday, February 11th at 1:45 p.m. in the Chelsea presentation room at the New York City Marriot Marquis.

Read More >

Wendy F. DiCicco joins Carmell Therapeutics' Board of Directors

Carmell Therapeutics, a pioneer in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, has named Wendy F. DiCicco to the Company’s Board of Directors.

Read More >

Toward a More Robust Regulatory Pathway — 3 Qs with Carmell Therapeutics' CEO Randy Hubbell

The FDA recently vowed to crackdown on unsubstantiated and poor quality stem cell therapies in 2019. Biologic-based products and other emerging medical technologies are at the center of a debate over the best regulatory pathways to ensure patient safety.

Read More >

Carmell Therapeutics President & CEO, Randy Hubbell, to Present at Biotech Showcase™ 2019 in San Francisco

PITTSBURGH, PA – Carmell Therapeutics, a pioneer in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, today announced its President and CEO, Randy Hubbell, will deliver a corporate presentation at Biotech Showcase™ 2019, on Tuesday, January 8, 2019 at 3:15 PM PST at the Hilton San Francisco Union Square in the Franciscan C ballroom.

Read More >

Archives


President and CEO, Randy Hubbell delivers a corporate presentation at the Investival Showcase at the Waldorf Hilton Hotel in London

Carmell Therapeutics President & CEO, Randy Hubbell, to Present at Investor and MedTech Conferences in November

Carmell Therapeutics Advances Plasma-based Products with $4M Series B Support

Carmell® Therapeutics is presenting at the Biotech and Money World Congress in London on 5-6th of February, 2018

Carmell Therapeutics Named Pittsburgh Tech 50 Awards Finalist

Stephanie Kladakis, Ph.D., Vice President, Research & Development, Carmell Therapeutics: Harvard School of Engineering and Applied Sciences Alumni Spotlight

Carmell™ Therapeutics closes $4M Series B round of funding

Carmell™ Therapeutics announced the issuance of Canadian Patent No. 2701187 for METHODS AND APPARATUS FOR MANUFACTURING PLASMA BASED PLASTICS

Carmell™ Therapeutics expands manufacturing capabilities to support Phase III clinical trials

Carmell Therapeutics New Management Team

Carmell announces the awarding of a new U.S. Patent that covers the use of the Company’s plasma-based materials as drug delivery vehicles

Dr. James Hart joins Carmell Therapeutics as new Chief Medical Officer

Randy Hubbell appointed as President and Chief Executive Officer

Carmell Therapeutics’ Plasma-Based Materials Shown to be Effective Antibiotic Delivery Vehicles

Research Notebook: Carmell Therapeutics’ PBMs—A new paradigm for healing tissue and bone

Carmell Therapeutics Ends 2014 with Addition of a New Patent to its Growing Portfolio

Pittsburgh researchers' bone putty could revolutionize how broken bones mend

Paper Describing Carmell Therapeutics’ Clinical Data Receives Coveted GT du Toit Award from the South African Orthopaedic Association

First Clinical Use of Carmell Therapeutics’ Plasma-Based Biomaterial Reduces Infections, Speeds Healing of Bone Fractures

Natural Infection Reduction: first reported use of a novel blood plasma-based product for treating open tibia fractures

Carmell Therapeutics Receives NIH Phase I Grant to develop antimicrobial-eluting bioresorbable bone filler.

Carmell Innovation Showcase Winner at ACA 2014 Summit

September 10, 2013: Five new U.S. Patents issued

Can New Plasma-Based Biomaterials Speed Healing of Injured Tissues?